Statistik Asas
| CIK | 1520047 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immunoclin Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| April 20, 2016 |
IMCL / Immunoclin Corporation / Castor Management Services Inc. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 IMMUNOCLIN CORPORATION (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 45256L 109 (CUSIP Number) Castor Management Services Inc. 9107 Wilshire Blvd., Suite 450 Beverly Hills, CA 90210 Attn: Mark Jordan, President 949.423.7127 (Name, |
|
| April 20, 2016 |
EX-1 2 t1600223ex1.htm EXHIBIT 1 Exhibit 1 MANAGEMENT AGREEMENT THIS AGREEMENT (the "Agreement") effective as of the Fifth (5th) day of April, 2013 (the “Effective Date”), entered into between Pharma Investing News, Inc., a Nevada Corporation, with its principal offices located at 1810 East Sahara Avenue, Suite 1571, Las Vegas, Nevada 89104 (the “Company” or “PINV”) and Castor Management Services |
|
| April 14, 2016 |
EX-4 2 t1600216ex4.htm EXHIBIT 4 Exhibit 4 STOCK PURCHASE AGREEMENT This AGREEMENT is made as of January 14, 2015, by and between Raymond C. Dabney (the "Purchaser"), an individual having an address of Suite 900-555 Burrard St., Vancouver, BC V7X 1M8 and Castor Management Services, Inc. (the "Seller"), a company incorporated under the laws of Nevada, having an address at 9107 Wilshire Blvd, Suite |
|
| April 14, 2016 |
IMCL / Immunoclin Corporation / Dabney Raymond C. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 IMMUNOCLIN CORPORATION (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 45256L 109 (CUSIP Number) Raymond C. Dabney Suite 900 555 – Burrard Street Vancouver BC, V7X 1M9 310.650.3788 (Name, Address and Telephone Number of Person Autho |
|
| April 11, 2016 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2016 IMMUNOCLIN CORPORATION (Exact name of registrant as specified in its charter) Nevada 000-54738 32-0337695 (State or Other Jurisdiction (Commission (I.R.S. Employer of In |
|
| April 4, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2016 IMMUNOCLIN CORPORATION (Exact name of registrant as specified in its charter) Nevada 000-54738 32-0337695 (State or Other Jurisdiction (Commission (I.R.S. Employer of In |
|
| April 4, 2016 |
Exhibit 16.1 Your Vision Our Focus April 4, 2016 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 We have read the statements of Immunoclin Corporation pertaining to our firm included under Item 4.01 of Form 8-K dated April 1, 2016, and agree with such statements as they pertain to our firm. Sincerely, /s/ Turner, Stone & Company, L.L.P. Turner, Stone & Company, L.L |
|
| March 29, 2016 |
IMCL / Immunoclin Corporation / JOHNSON CHAD STEVEN - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. )* Under the Securities Exchange Act of 1934 Immunoclin Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45256L 109 (CUSIP Number) Chad Steven Johnson c/o Immunoclin Corporation 1420 N Street, Suite 102 NW, Washington, DC 20005, USA 888-267-1175 (Name, Address and Telephone N |
|
| March 29, 2016 |
IMCL / Immunoclin Corporation / Benlhassan Khadija - SCHEDULE 13D Activist Investment SC 13D 1 v435131sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. )* Under the Securities Exchange Act of 1934 Immunoclin Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45256L 109 (CUSIP Number) Dr. Khadija Benlhassan c/o Immunoclin Corporation 1420 N Street, Suite 102 NW, Washington, DC 20005, USA 8 |
|
| March 29, 2016 |
ADDENDUM TO MANAGEMENT AGREEMENT Exhibit 6 ADDENDUM TO MANAGEMENT AGREEMENT THIS ADDENDUM (the "Addendum") dated as of the thirtieth (30th) day of May 2014 to the MANAGEMENT AGREEMENT (the "Agreement") dated as of the twenty third (23rd) day of January 2014, entered into between Immunoclin Corporation, a Nevada corporation, with its principal offices located at 9107 Wilshire Blvd, Suite 450, Beverly Hills, CA 90210 (the “Company” |
|
| March 29, 2016 |
ADDENDUM TO MANAGEMENT AGREEMENT EX-99.4 2 v435131ex99-4.htm EXHIBIT 4 Exhibit 4 ADDENDUM TO MANAGEMENT AGREEMENT THIS ADDENDUM (the "Addendum") dated as of the tenth (10th) day of November 2014 to the MANAGEMENT AGREEMENT (the "Agreement") dated as of the Twenty-third (23rd) day of January 2014, entered into between Immunoclin Corporation, a Nevada corporation, with its principal offices located at 1800 Wyoming Avenue NW, 3rd Fl |
|
| March 29, 2016 |
IMCL / Immunoclin Corporation / Bray Dr Dorothy H - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. )* Under the Securities Exchange Act of 1934 Immunoclin Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45256L 109 (CUSIP Number) Dr. Dorothy H. Bray c/o Immunoclin Corporation 1420 N Street, Suite 102 NW, Washington, DC 20005, USA 888-267-1175 (Name, Address and Telephone N |
|
| March 29, 2016 |
ADDENDUM TO MANAGEMENT AGREEMENT Exhibit 5 ADDENDUM TO MANAGEMENT AGREEMENT THIS ADDENDUM (the "Addendum") dated as of the thirtieth (30th) day of October 2014 to the MANAGEMENT AGREEMENT (the "Agreement") dated as of the Twenty-third (23rd) day of January 2014, entered into between Immunoclin Corporation, a Nevada corporation, with its principal offices located at 1800 Wyoming Avenue NW, 3rd Floor, Washington, DC 20009 USA (the “Company”) and Dr. |
|
| March 29, 2016 |
IMCL / Immunoclin Corporation / MUNRO JAMES SCOTT - SC 13D Activist Investment SC 13D 1 v435130sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. )* Under the Securities Exchange Act of 1934 Immunoclin Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45256L 109 (CUSIP Number) James Scott Munro c/o Immunoclin Corporation 1420 N Street, Suite 102 NW, Washington, DC 20005, USA 888-267-1175 |
|
| March 11, 2016 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2016 IMMUNOCLIN CORPORATION (Exact name of registrant as specified in its charter) Nevada 000-54738 32-0337695 (State or Other Jurisdiction (Commission (I.R.S. Employer of I |
|
| May 4, 2015 |
Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Form NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 45256L 109 [ X |
|
| December 22, 2014 |
Immunoclin FORM 10-Q (Quarterly Report) 10-Q 1 form10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 31, 2014 □ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 000-54738 IMMUNOCLIN CORPORATIO |
|
| December 22, 2014 |
EX-10.3 4 exhibit103.htm EXHIBIT 10.3 PRODUCT MARKETING SERVICE AGREEMENT This Agreement is made effective as of October 31, 2014 by and between: Mr. Kamal Etefia,an individual having an address at 2 Allée Scheurer Kestner 92150 SURESNES, France (the “Provider”) AND ImmunoClin Corporation, 1800 Wyoming Avenue, NW, 3rd Floor, Washington, DC 20009 USA, represented by Dr. Dorothy Bray, acting as Dire |
|
| December 22, 2014 |
BUSINESS DEVELOPMENT SERVICE AGREEMENT EX-10.1 2 exhibit101.htm EXHIBIT 10.1 BUSINESS DEVELOPMENT SERVICE AGREEMENT This Agreement is made effective as of August 11, 2014 by and between: JAGPAL HOLDINGS INC, a company organized and existing under the laws of Belize, with its principal place of business located at 1 Mapp Street, Belize City, Belize represented by Mr. Amandip Jagpal, acting as President (the “Provider”) AND ImmunoClin Co |
|
| December 22, 2014 |
BUSINESS DEVELOPMENT SERVICE AGREEMENT EX-10.2 3 exhibit102.htm EXHIBIT 10.2 BUSINESS DEVELOPMENT SERVICE AGREEMENT This Agreement is made effective as of October 31, 2014 by and between: E.G.P.C. FINANCE, a company organized and existing under the laws of France, with its principal place of business located at 2 Allée Scheurer Kestner 92150 SURESNES, France represented by Mr. Kamal Etefia, acting as Director (the “Provider”) AND Immun |
|
| December 15, 2014 |
IMCL / Immunoclin Corporation NT 10-Q - - FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 45256L 109 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio |
|
| December 3, 2014 |
IMMUNOCLIN CORPORATION 2014 Stock Compensation Plan SECTION 1 EX-4.1 2 exhibit41.htm EXHIBIT 4.1 IMMUNOCLIN CORPORATION 2014 Stock Compensation Plan SECTION 1 INTRODUCTION 1.1 Establishment. ImmunoClin Corporation (the “Company”), a Nevada corporation, hereby establishes the ImmunoClin Corporation 2014 Non-qualified Stock Compensation Plan (the “Plan”) for employees, consultants, directors, and other persons associated with the Company and any of the Company |
|
| December 3, 2014 |
IMCL / Immunoclin Corporation S-8 - - FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOCLIN CORPORATION (Exact name of Registrant as specified in its charter) Nevada 32-0337695 (State or Other Jurisdiction of Incorporation of Organization) (I.R.S. Employer Identification No.) 1800 Wyoming Avenue NW 3rd Floor Washington, DC 20009 (Address of p |
|
| September 29, 2014 |
Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Exhibit 10.1 DEBT SETTLEMENT AGREEMENT THIS AGREEMENTis dated for reference the 11th day of August 2014. BETWEEN: Immunoclin Corporation, a company incorporated under the laws of Nevada and having an office at 1800 Wyoming Avenue NW, 3rd Floor Washington, DC 20009 USA (the ?Company?) OF THE FIRST PART A |
|
| September 29, 2014 |
Immunoclin FORM 10-Q (Quarterly Report) Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 31, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A |
|
| September 15, 2014 |
IMCL / Immunoclin Corporation NT 10-Q - - FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 45256L 109 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio |
|
| August 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2014 IMMUNOCLIN CORPORATION (Exact name of registrant as specified in charter) Nevada 000-54738 32-0337695 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 24, 2014 |
Immunoclin FORM 10-Q (Quarterly Report) Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 30, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT For the transi |
|
| July 8, 2014 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2014 IMMUNOCLIN CORPORATION (Exact name of registrant as specified in charter) Nevada 000-54738 32-0337695 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 8, 2014 |
Securities and Exchange Commission EX-16.1 2 exhibit161.htm EXHIBIT 16.1 July 7, 2014 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 We have read the statements of ImmunoClin Corporation pertaining to our firm included under Item 4.01 of Form 8-K dated January 7, 2014, and agree with such statements as they pertain to our firm. Sincerely, /s/ Sadler, Gibb & Associates, LLC |
|
| July 7, 2014 |
Immunoclin FORM 10-K/A (Annual Report) Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Form 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended January 31, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT F |
|
| July 2, 2014 |
Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Exhibit 10.7 |
|
| July 2, 2014 |
Immunoclin FORM 10-K (Annual Report) 10-K 1 form10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended January 31, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT For the transition year from Commission File Number: 333-174271 IMMUNOCLIN CORPORATION (Exact name |
|
| June 16, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 45256L 109 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio |
|
| May 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 45256L 109 [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| March 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2014 IMMUNOCLIN CORPORATION (Name of Small Business Issuer in its charter) Nevada 000-54738 32-0337695 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 4, 2014 |
EXECUTIVE MANAGEMENT AND BONUS AGREEMENT EX-10.1 2 exhibit101.htm EXHIBIT 10.1 EXECUTIVE MANAGEMENT AND BONUS AGREEMENT THIS AGREEMENT (the "Agreement") effective as of this Twenty-third (23rd) day of January 2014 (the “Effective Date”), entered into between Pharma Investing News, Inc. a Nevada Corporation, with its principal offices located at 9107 Wilshire Blvd, Suite 450, Beverly Hills, CA 90210 (the “Company” or “PINV”) and Dr. Khadi |
|
| February 27, 2014 |
IMMUNOCLIN CORPORATION Unaudited Pro Forma Condensed Combined Balance Sheet November 30, 2013 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED COMBINED FINANCIAL INFORMATION On December 13, 2013, Immunoclin Corporation (formerly Pharma Investing News, Inc.) (the ‘‘Company,’’ ‘‘we,’’ ‘‘our’’ or ‘‘us’’) completed the acquisition of Immunoclin Limited, and England and Wales company (‘‘IML’’). The accompanying unaudited pro forma condensed consolidated combined balance sheet as of Novem |
|
| February 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2013 IMMUNOCLIN CORPORATION (Name of Small Business Issuer in its charter) Nevada 000-54738 32-0337695 (State or other jurisdiction of incorporation) (C |
|
| February 6, 2014 |
SCHEDULE “A” CERTIFICATE OF DESIGNATION PREFERENCES AND RIGHTS of SERIES A PREFERRED STOCK (Pursuant to Section 78. |
|
| February 6, 2014 |
8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2014 IMMUNOCLIN CORPORATION (Exact name of registrant as specified in charter) Nevada 000-54738 32-0337695 (State or other jurisdiction of incor |
|
| January 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 71711A 108 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio |
|
| December 20, 2013 |
MANAGEMENT AND BONUS AGREEMENT MANAGEMENT AND BONUS AGREEMENT THIS AGREEMENT (the "Agreement") effective as of this thirteenth (13th) day of December 2013 (the “Effective Date”), entered into between Pharma Investing News, Inc. |
|
| December 20, 2013 |
CONTROL SHAREHOLDER AGREEMENT THIS CONTROL SHAREHOLDER AGREEMENT(this “Agreement”) made effective as of the 13th day of December 2013 (the “Effective Date”), BETWEEN: Pharma Investing News, Inc. |
|
| December 20, 2013 |
EXECUTIVE MANAGEMENT AND BONUS AGREEMENT EXECUTIVE MANAGEMENT AND BONUS AGREEMENT THIS AGREEMENT (the "Agreement") effective as of this thirteenth (13th) day of December 2013 (the “Effective Date”), entered into between Pharma Investing News, Inc. |
|
| December 20, 2013 |
EXECUTIVE MANAGEMENT AND BONUS AGREEMENT EXECUTIVE MANAGEMENT AND BONUS AGREEMENT THIS AGREEMENT (the "Agreement") effective as of this thirteenth (13th) day of December 2013 (the “Effective Date”), entered into between Pharma Investing News, Inc. |
|
| December 20, 2013 |
TAKEOVER AGREEMENT This Takeover Agreement ("Agreement") is entered into as of December 13, 2013 by and between: Pharma Investing News, Inc. |
|
| December 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2013 PHARMA INVESTING NEWS, INC. (Name of Small Business Issuer in its charter) Nevada 32-0337695 (state or other jurisdiction of incorporation or organization) (I.R.S. E |
|
| December 20, 2013 |
CONTROL SHAREHOLDER AGREEMENT THIS CONTROL SHAREHOLDER AGREEMENT(this “Agreement”) made effective as of the 13th day of December 2013 (the “Effective Date”), BETWEEN: Pharma Investing News, Inc. |
|
| December 20, 2013 |
EXECUTIVE MANAGEMENT AND BONUS AGREEMENT EXECUTIVE MANAGEMENT AND BONUS AGREEMENT THIS AGREEMENT (the "Agreement") effective as of this thirteenth (13th) day of December 2013 (the “Effective Date”), entered into between Pharma Investing News, Inc. |
|
| October 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 71711A 108 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio |
|
| July 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 71711A 108 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio |
|
| May 29, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 000-54738 CUSIP NUMBER 71711A 108 [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| May 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2013 PHARMA INVESTING NEWS, INC. (Exact name of registrant as specified in charter) Nevada 000-54738 32-0337695 (State or other jurisdiction of incorporation) (Commission F |
|
| January 14, 2013 |
- FORM 12B-25 NOTIFICATION OF LATE FILING Form 12b-25 Notification of Late Filing U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 333-174271 CUSIP NUMBER 71711A 108 . Form 10-K . Form 20-F . Form 11-K X . Form 10-Q . Form 10-D . Form N-SAR . Form N-CSR For period ended: November 30, 2012 . Transition Report on Form 10-K . Transition Report on Form 20-F . Transition Rep |
|
| October 16, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2012 Pharma Investing News, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54738 (Commissi |
|
| June 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 PHARMA INVESTING NEWS, INC. |
|
| June 1, 2012 |
FORM 424(b)(3) Filed pursuant to Rule 424(b)(3) Registration No. 333-174271 AMENDMENT TO SUPPLEMENT NO. 2 DATED MAY 31, 2012 TO PROSPECTUS DATED SEPTEMBER 8, 2011 PHARMA INVESTING NEWS, INC. The following information supplements the prospectus of Pharma Investing News, Inc. dated September 8, 2011 and is part of the prospectus. This Amendment to Supplement No. 2 updates the information presented i |
|
| May 30, 2012 |
Prospectus Supplement No. 2 Filed pursuant to Rule 424(b)(3) Registration No. 333-174271 SUPPLEMENT NO. 2 DATED MAY 30, 2012 TO PROSPECTUS DATED SEPTEMBER 8, 2011 PHARMA INVESTING NEWS, INC. The following information supplements the prospectus of Pharma Investing News, Inc. dated September 8, 2011 and is part of the prospectus. This Supplement updates the information presented in the prospectus. P |
|
| May 29, 2012 |
- EXTENSION FOR FEBRUARY 29, 2012 10-K U.S. SECURITIES AND EXCHANGE COMMISSION SEC FILE NUMBER Washington, D.C. 20549 333-174271 FORM 12b-25 CUSIP NUMBER NOTIFICATION OF LATE FILING 71711A 108 X . Form 10-K . Form 20-F . Form 11-K . Form 10-Q . Form 10-D . Form N-SAR . Form N-CSR For period ended: February 29, 2012 . Transition Report on Form 10-K . Transition Report on Form 20-F . Transition Report on Form 11-K . Transition Report on |
|
| March 15, 2012 |
Form 424(b)(3) Filed pursuant to Rule 424(b)(3) Registration No. 333-174271 SUPPLEMENT NO. 1 DATED MARCH 15, 2012 TO PROSPECTUS DATED SEPTEMBER 8, 2011. PHARMA INVESTING NEWS, INC. The following information supplements the prospectus of Pharma Investing News, Inc. dated September 8, 2011 and is part of the prospectus. This Supplement updates the information presented in the prospectus. Prospective |
